Modification of daunorubicin-GnRH-III bioconjugates with oligoethylene glycol derivatives to improve solubility and bioavailability for targeted cancer chemotherapy

Rózsa Hegedüs, Aline Pauschert, Erika Orbán, Ildikó Szabó, David Andreu, Andreas Marquardt, G. Mező, Marilena Manea

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Daunorubicin-GnRH-III bioconjugates have recently been developed as drug delivery systems with potential applications in targeted cancer chemotherapy. In order to improve their biochemical properties, several strategies have been pursued: (1) incorporation of an enzymatic cleavable spacer between the anticancer drug and the peptide-based targeting moiety, (2) peptide modification by short chain fatty acids, or (3) attachment of two anticancer drugs to the same GnRH-III derivative. Although these modifications led to more potent bioconjugates, a decrease in their solubility was observed. Here we report on the design, synthesis and biochemical characterization of daunorubicin-GnRH-III bioconjugates with increased solubility, which could be achieved by incorporating oligoethylene glycol-based spacers in their structure. First, we have evaluated the effect of an oligoethylene glycol-based spacer on the solubility, enzymatic stability/degradation, cellular uptake, and in vitro cytostatic effect of a bioconjugate containing only one daunorubicin attached through a GFLG tetrapeptide spacer to the GnRH-III targeting moiety. Thereafter, more complex compounds containing two copies of daunorubicin, GFLG spacers as well as Lys(nBu) in position 4 of GnRH-III were synthesized and biochemically characterized. Our results indicated that all synthesized oligoethylene glycol-containing bioconjugates had higher solubility in cell culture medium than the unmodified analogs. They were degraded in the presence of rat liver lysosomal homogenate leading to the formation of small drug containing metabolites. In the case of bioconjugates containing two copies of daunorubicin, the incorporation of oligoethylene glycol-based spacers led to increased in vitro cytostatic effect on MCF-7 human breast cancer cells.

Original languageEnglish
Pages (from-to)167-177
Number of pages11
JournalBiopolymers
Volume104
Issue number3
DOIs
Publication statusPublished - May 1 2015

Fingerprint

Glycols
Daunorubicin
Chemotherapy
Solubility
Biological Availability
Derivatives
Drug Therapy
Cytostatic Agents
Neoplasms
Peptides
Pharmaceutical Preparations
Volatile Fatty Acids
Drug Delivery Systems
Metabolites
Fatty acids
Cell culture
Liver
Culture Media
Rats
Cell Culture Techniques

Keywords

  • cytostatic effect
  • daunorubicin
  • drug delivery systems
  • enhanced solubility
  • gonadotropin-releasing hormone
  • oligoethylene glycol

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Modification of daunorubicin-GnRH-III bioconjugates with oligoethylene glycol derivatives to improve solubility and bioavailability for targeted cancer chemotherapy. / Hegedüs, Rózsa; Pauschert, Aline; Orbán, Erika; Szabó, Ildikó; Andreu, David; Marquardt, Andreas; Mező, G.; Manea, Marilena.

In: Biopolymers, Vol. 104, No. 3, 01.05.2015, p. 167-177.

Research output: Contribution to journalArticle

Hegedüs, Rózsa ; Pauschert, Aline ; Orbán, Erika ; Szabó, Ildikó ; Andreu, David ; Marquardt, Andreas ; Mező, G. ; Manea, Marilena. / Modification of daunorubicin-GnRH-III bioconjugates with oligoethylene glycol derivatives to improve solubility and bioavailability for targeted cancer chemotherapy. In: Biopolymers. 2015 ; Vol. 104, No. 3. pp. 167-177.
@article{5c95a5e4108b4175b678527ae50ddf4a,
title = "Modification of daunorubicin-GnRH-III bioconjugates with oligoethylene glycol derivatives to improve solubility and bioavailability for targeted cancer chemotherapy",
abstract = "Daunorubicin-GnRH-III bioconjugates have recently been developed as drug delivery systems with potential applications in targeted cancer chemotherapy. In order to improve their biochemical properties, several strategies have been pursued: (1) incorporation of an enzymatic cleavable spacer between the anticancer drug and the peptide-based targeting moiety, (2) peptide modification by short chain fatty acids, or (3) attachment of two anticancer drugs to the same GnRH-III derivative. Although these modifications led to more potent bioconjugates, a decrease in their solubility was observed. Here we report on the design, synthesis and biochemical characterization of daunorubicin-GnRH-III bioconjugates with increased solubility, which could be achieved by incorporating oligoethylene glycol-based spacers in their structure. First, we have evaluated the effect of an oligoethylene glycol-based spacer on the solubility, enzymatic stability/degradation, cellular uptake, and in vitro cytostatic effect of a bioconjugate containing only one daunorubicin attached through a GFLG tetrapeptide spacer to the GnRH-III targeting moiety. Thereafter, more complex compounds containing two copies of daunorubicin, GFLG spacers as well as Lys(nBu) in position 4 of GnRH-III were synthesized and biochemically characterized. Our results indicated that all synthesized oligoethylene glycol-containing bioconjugates had higher solubility in cell culture medium than the unmodified analogs. They were degraded in the presence of rat liver lysosomal homogenate leading to the formation of small drug containing metabolites. In the case of bioconjugates containing two copies of daunorubicin, the incorporation of oligoethylene glycol-based spacers led to increased in vitro cytostatic effect on MCF-7 human breast cancer cells.",
keywords = "cytostatic effect, daunorubicin, drug delivery systems, enhanced solubility, gonadotropin-releasing hormone, oligoethylene glycol",
author = "R{\'o}zsa Heged{\"u}s and Aline Pauschert and Erika Orb{\'a}n and Ildik{\'o} Szab{\'o} and David Andreu and Andreas Marquardt and G. Mező and Marilena Manea",
year = "2015",
month = "5",
day = "1",
doi = "10.1002/bip.22629",
language = "English",
volume = "104",
pages = "167--177",
journal = "Biopolymers",
issn = "0006-3525",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Modification of daunorubicin-GnRH-III bioconjugates with oligoethylene glycol derivatives to improve solubility and bioavailability for targeted cancer chemotherapy

AU - Hegedüs, Rózsa

AU - Pauschert, Aline

AU - Orbán, Erika

AU - Szabó, Ildikó

AU - Andreu, David

AU - Marquardt, Andreas

AU - Mező, G.

AU - Manea, Marilena

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Daunorubicin-GnRH-III bioconjugates have recently been developed as drug delivery systems with potential applications in targeted cancer chemotherapy. In order to improve their biochemical properties, several strategies have been pursued: (1) incorporation of an enzymatic cleavable spacer between the anticancer drug and the peptide-based targeting moiety, (2) peptide modification by short chain fatty acids, or (3) attachment of two anticancer drugs to the same GnRH-III derivative. Although these modifications led to more potent bioconjugates, a decrease in their solubility was observed. Here we report on the design, synthesis and biochemical characterization of daunorubicin-GnRH-III bioconjugates with increased solubility, which could be achieved by incorporating oligoethylene glycol-based spacers in their structure. First, we have evaluated the effect of an oligoethylene glycol-based spacer on the solubility, enzymatic stability/degradation, cellular uptake, and in vitro cytostatic effect of a bioconjugate containing only one daunorubicin attached through a GFLG tetrapeptide spacer to the GnRH-III targeting moiety. Thereafter, more complex compounds containing two copies of daunorubicin, GFLG spacers as well as Lys(nBu) in position 4 of GnRH-III were synthesized and biochemically characterized. Our results indicated that all synthesized oligoethylene glycol-containing bioconjugates had higher solubility in cell culture medium than the unmodified analogs. They were degraded in the presence of rat liver lysosomal homogenate leading to the formation of small drug containing metabolites. In the case of bioconjugates containing two copies of daunorubicin, the incorporation of oligoethylene glycol-based spacers led to increased in vitro cytostatic effect on MCF-7 human breast cancer cells.

AB - Daunorubicin-GnRH-III bioconjugates have recently been developed as drug delivery systems with potential applications in targeted cancer chemotherapy. In order to improve their biochemical properties, several strategies have been pursued: (1) incorporation of an enzymatic cleavable spacer between the anticancer drug and the peptide-based targeting moiety, (2) peptide modification by short chain fatty acids, or (3) attachment of two anticancer drugs to the same GnRH-III derivative. Although these modifications led to more potent bioconjugates, a decrease in their solubility was observed. Here we report on the design, synthesis and biochemical characterization of daunorubicin-GnRH-III bioconjugates with increased solubility, which could be achieved by incorporating oligoethylene glycol-based spacers in their structure. First, we have evaluated the effect of an oligoethylene glycol-based spacer on the solubility, enzymatic stability/degradation, cellular uptake, and in vitro cytostatic effect of a bioconjugate containing only one daunorubicin attached through a GFLG tetrapeptide spacer to the GnRH-III targeting moiety. Thereafter, more complex compounds containing two copies of daunorubicin, GFLG spacers as well as Lys(nBu) in position 4 of GnRH-III were synthesized and biochemically characterized. Our results indicated that all synthesized oligoethylene glycol-containing bioconjugates had higher solubility in cell culture medium than the unmodified analogs. They were degraded in the presence of rat liver lysosomal homogenate leading to the formation of small drug containing metabolites. In the case of bioconjugates containing two copies of daunorubicin, the incorporation of oligoethylene glycol-based spacers led to increased in vitro cytostatic effect on MCF-7 human breast cancer cells.

KW - cytostatic effect

KW - daunorubicin

KW - drug delivery systems

KW - enhanced solubility

KW - gonadotropin-releasing hormone

KW - oligoethylene glycol

UR - http://www.scopus.com/inward/record.url?scp=84980028112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84980028112&partnerID=8YFLogxK

U2 - 10.1002/bip.22629

DO - 10.1002/bip.22629

M3 - Article

C2 - 25753049

AN - SCOPUS:84980028112

VL - 104

SP - 167

EP - 177

JO - Biopolymers

JF - Biopolymers

SN - 0006-3525

IS - 3

ER -